INmune Bio Inc (NASDAQ:INMB) major shareholder Mark William Lowdell acquired 2,918 shares of the company’s stock in a transaction on Wednesday, September 11th. The shares were purchased at an average cost of $6.23 per share, with a total value of $18,179.14. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of INMB opened at $5.91 on Thursday. INmune Bio Inc has a 12-month low of $5.06 and a 12-month high of $11.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 20.94 and a quick ratio of 20.94. The firm has a fifty day moving average price of $6.57 and a 200-day moving average price of $8.77.
INmune Bio (NASDAQ:INMB) last issued its earnings results on Monday, August 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.16. On average, sell-side analysts anticipate that INmune Bio Inc will post -0.65 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on INMB. HC Wainwright reissued a “buy” rating and set a $11.50 target price on shares of INmune Bio in a research note on Thursday, September 12th. Maxim Group set a $13.00 target price on shares of INmune Bio and gave the company a “buy” rating in a research note on Friday, September 13th.
An institutional investor recently raised its position in INmune Bio stock. BlackRock Inc. grew its stake in shares of INmune Bio Inc (NASDAQ:INMB) by 1,556.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,048 shares of the company’s stock after purchasing an additional 2,864 shares during the quarter. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 at the end of the most recent quarter. Institutional investors own 0.36% of the company’s stock.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.